High Cholesterol

Clinical Trial Finder

Many patients with high cholesterol are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

Condition:   Hypercholesterolemia
Interventions:   Drug: alirocumab SAR236553/REGN727;   Drug: placebo
Sponsor:   Sanofi
Recruiting - verified April 2015

Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Condition:   Hypercholesterolemia
Intervention:   Biological: Evolocumab
Sponsor:   Amgen
Enrolling by invitation - verified April 2015

Use of Decision Aids in Clinical Encounters

Condition:   Diabetes, Depression, Cardiovascular Disease,Hypercholesterolemia, Osteoporosis
Interventions:   Other: Active Implementation of ShareEBM Toolkit;   Other: Passive Dissemination of Share EBM
Sponsor:   Mayo Clinic
Enrolling by invitation - verified April 2015

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

Condition:   Hypercholesterolemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: Placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Active, not recruiting - verified April 2015

Open Label Study of Long Term Safety Evaluation of Alirocumab

Condition:   Hypercholesterolemia
Intervention:   Drug: Alirocumab SAR236553 (REGN727)
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Enrolling by invitation - verified April 2015

Relationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia

Conditions:   Low CETP Activity;   CETP Deficiency;   Hyperalphalipoproteinemia;   Hyper-LDL-cholesterolemia;   High Level of Remnant Cholesterol
Intervention:  
Sponsors:   Osaka University;   Merck Sharp & Dohme Corp.
Recruiting - verified August 2013

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)

Condition:   Hypercholesterolemia
Interventions:   Drug: Anacetrapib;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified April 2015

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)

Condition:   Hypercholesterolemia
Interventions:   Drug: Anacetrapib 100 mg;   Drug: Placebo for anacetrapib 100 mg;   Drug: Anacetrapib 25 mg;   Drug: Placebo for anacetrapib 25 mg
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2015

Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

Conditions:   Hyperlipoproteinemia Type II;   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: Anacetrapib;   Drug: Placebo for Anacetrapib
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified April 2015

Switch to Unboosted Atazanavir With Tenofovir Study

Condition:   HIV Infection
Interventions:   Drug: atazanavir;   Drug: atazanavir/ritonavir
Sponsor:   University of British Columbia
Active, not recruiting - verified April 2015

Youth Lifestyle Intervention With Food and Exercise

Conditions:   Healthy;   Obesity
Interventions:   Behavioral: 2 servings dairy + exercise;   Behavioral: 4 servings dairy + exercise;   Behavioral: Control
Sponsors:   McGill University;   Dairy Farmers of Canada
Completed - verified April 2015

Hispanics With Metabolic Syndrome and Non-ischemic Heart Failure

Conditions:   Metabolic Syndrome;   Heart Failure
Intervention:  
Sponsors:   Texas Tech University Health Sciences Center;   Health Resources and Services Administration (HRSA)
Withdrawn - verified April 2015

Effects of Vitamin D on Lipids

Conditions:   Hypercholesterolemia;   Vitamin D Deficiency
Interventions:   Dietary Supplement: Vitamin D (1000 or 2000 IU/day);   Other: Placebo
Sponsors:   University of California, San Francisco;   National Institute on Aging (NIA)
Completed - verified April 2015

Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)

Conditions:   Hypercholesterolemia;   Atherosclerosis
Interventions:   Drug: Ezetimibe + Atorvastatin;   Drug: Atorvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2015

Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)

Conditions:   Hypercholesterolaemia;   Atherosclerosis
Interventions:   Drug: Ezetimibe + Simvastatin;   Drug: Simvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2015

Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)

Conditions:   Hypercholesterolemia;   Atherosclerosis
Interventions:   Drug: Ezetimibe + Simvastatin;   Drug: Simvastatin;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified April 2015

Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)

Condition:   Hypercholesterolemia
Interventions:   Drug: Ezetimibe + Simvastatin;   Drug: Simvastatin;   Drug: Ezetimibe
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2015

Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)

Conditions:   Hypercholesterolemia;   Atherosclerosis
Interventions:   Drug: Ezetimibe + Simvastatin;   Drug: Simvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2015

Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)

Conditions:   Hypercholesterolemia;   Atherosclerosis
Interventions:   Drug: Ezetimibe;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2015

Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)

Conditions:   Atherosclerosis;   Hypercholesterolemia;   Coronary Heart Disease
Interventions:   Drug: Ezetimibe;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2015

Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)

Conditions:   Hypercholesterolemia;   Atherosclerosis
Interventions:   Drug: Ezetimibe;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Merck Frosst Canada Ltd.
Terminated - verified April 2015

Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)

Conditions:   Hypercholesterolemia;   Atherosclerosis
Interventions:   Drug: Ezetimibe + Rosuvastatin;   Drug: Rosuvastatin;   Drug: Placebo;   Drug: Ezetimibe
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2015

Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)

Condition:   Hypercholesterolemia
Interventions:   Drug: SCH 58235;   Drug: pitavastatin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2015

Causes and Natural History of Dyslipidemias

Condition:   Dyslipidemias
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2015

Evaluation of Lipoproteins

Conditions:   Hyperlipidemia;   Hyperlipoproteinemia;   Hypolipoproteinemia
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2015

Get CardioSmart

You're Invited